This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects
Voluntarily sign the ICF..
BMI between 18-26 kg/m² (inclusive). Male weight ≥50 kg; female weight ≥45 kg.
Vital signs, physical examination, ECG, Chest X-ray, Abdominal ultrasound results at screening are within normal range or showing minor deviations deemed not clinically significant by the investigator.
Laboratory test results at screening and baseline are within the normal reference range.
Evidence or history of clinically significant diseases, or Evidence or history of allergic diseases .
Clinically significant gastrointestinal dysfunction that may affect drug intake, transport, or absorption.
Acute illness within 14 days before dosing.
Severe infection within 6 months before dosing, or chronic/recurrent infections.